{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:15:27Z","timestamp":1788120927524,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13760-019-01209-0","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T13:10:16Z","timestamp":1569417016000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2821-9042","authenticated-orcid":false,"given":"Bruno Kusznir","family":"Vitturi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Pellegrinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice Cataldo Oliveira","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"1209_CR1","doi-asserted-by":"publisher","first-page":"874680","DOI":"10.1155\/2012\/874680","volume":"2012","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012) Myasthenia gravis: a review. Autoimmune Dis 2012:874680. \nhttps:\/\/doi.org\/10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"issue":"10","key":"1209_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"12","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","volume":"61","author":"DP Richman","year":"2003","unstructured":"Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61(12):1652\u20131661. \nhttps:\/\/doi.org\/10.1212\/01.WNL.0000098887.24618.A0","journal-title":"Neurology"},{"issue":"3","key":"1209_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British neurologists\u2019 management guidelines. Pract Neurol 15(3):199\u2013206. \nhttps:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"issue":"3","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JND-170294","volume":"5","author":"A Behin","year":"2018","unstructured":"Behin A, Le Panse R (2018) New pathways and therapeutic targets in autoimmune myasthenia gravis. J Neuromuscul Dis 5(3):265\u2013277. \nhttps:\/\/doi.org\/10.3233\/JND-170294","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Drug therapy: adherence to medication. N Engl J Med 353(5):487\u2013497. \nhttps:\/\/doi.org\/10.1056\/NEJMra050100","journal-title":"N Engl J Med"},{"issue":"7","key":"1209_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/j.1468-1331.2010.03320.x","volume":"18","author":"F Valldeoriola","year":"2011","unstructured":"Valldeoriola F, Coronell C, Pont C et al (2011) Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson\u2019s disease: the ADHESON study. Eur J Neurol 18(7):980\u2013987. \nhttps:\/\/doi.org\/10.1111\/j.1468-1331.2010.03320.x","journal-title":"Eur J Neurol"},{"issue":"12","key":"1209_CR8","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/epi.13586","volume":"57","author":"L de Ernst","year":"2016","unstructured":"de Ernst L, Harden CL, Pennel PB et al (2016) Medication adherence in women with epilepsy who are planning pregnancy. Epilepsia 57(12):2039\u20132044. \nhttps:\/\/doi.org\/10.1111\/epi.13586","journal-title":"Epilepsia"},{"key":"1209_CR9","first-page":"15","volume":"66","author":"JF Idi\u00e1quez","year":"2018","unstructured":"Idi\u00e1quez JF, Gonz\u00e1lez S, Lasso-Pe\u00f1afiel J, Barnett C (2018) Adhesi\u00f3n al tratamiento farmacol\u00f3gico y descripci\u00f3n de sus factores asociados en pacientes con miastenia grave. Rev Neurol 66:15\u201320","journal-title":"Rev Neurol"},{"issue":"1","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1212\/WNL.55.1.16","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Ann Thorac Surg 70(1):327\u2013334. \nhttps:\/\/doi.org\/10.1212\/WNL.55.1.16","journal-title":"Ann Thorac Surg"},{"issue":"18","key":"1209_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB (2010) The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74(18):1434\u20131440. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e","journal-title":"Neurology"},{"issue":"1","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","volume":"43","author":"TM Burns","year":"2011","unstructured":"Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB (2011) The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43(1):14\u201318. \nhttps:\/\/doi.org\/10.1002\/mus.21883","journal-title":"Muscle Nerve"},{"issue":"6","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2013370. \nhttps:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.sapharm.2013.10.006","volume":"10","author":"AD de Oliveira-Filho","year":"2014","unstructured":"de Oliveira-Filho AD, Morisky DE, Neves SJF, Costa FA, De Lyra DP (2014) The 8-item Morisky Medication Adherence Scale: validation of a Brazilian\u2013Portuguese version in hypertensive adults. Res Soc Adm Pharm 10(3):554\u2013561. \nhttps:\/\/doi.org\/10.1016\/j.sapharm.2013.10.006","journal-title":"Res Soc Adm Pharm"},{"issue":"4","key":"1209_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86(4):304\u2013314. \nhttps:\/\/doi.org\/10.4065\/mcp.2010.0575","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.seizure.2013.02.006","volume":"22","author":"CMM Ferrari","year":"2013","unstructured":"Ferrari CMM, De Sousa RMC, Castro LHM (2013) Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure 22(5):384\u2013389. \nhttps:\/\/doi.org\/10.1016\/j.seizure.2013.02.006","journal-title":"Seizure"},{"issue":"1\u20132","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2012.03.018","volume":"318","author":"D Santos-Garc\u00eda","year":"2012","unstructured":"Santos-Garc\u00eda D, Prieto-Formoso M, De La Fuente-Fern\u00e1ndez R (2012) Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson\u2019s disease. J Neurol Sci 318(1\u20132):90\u201393. \nhttps:\/\/doi.org\/10.1016\/j.jns.2012.03.018","journal-title":"J Neurol Sci"},{"issue":"2","key":"1209_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/1817-1737.109823","volume":"8","author":"A Alkatheri","year":"2013","unstructured":"Alkatheri A, Albekairy A (2013) Does the patients\u2019 educational level and previous counseling affect their medication knowledge? Ann Thorac Med 8(2):105\u2013108. \nhttps:\/\/doi.org\/10.4103\/1817-1737.109823","journal-title":"Ann Thorac Med"},{"issue":"1","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/01.CPJ.0000436211.73013.ab","volume":"4","author":"J Fleisher","year":"2014","unstructured":"Fleisher J, Bhatia R, Margus C, Pruitt A, Dahodwala N (2014) Health literacy and medication awareness in outpatient neurology. Neurol Clin Pract 4(1):71\u201381. \nhttps:\/\/doi.org\/10.1212\/01.CPJ.0000436211.73013.ab","journal-title":"Neurol Clin Pract"},{"key":"1209_CR20","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.cd000011.pub4","volume":"11","author":"R Nieuwlaat","year":"2014","unstructured":"Nieuwlaat R, Wilczynski N, Navarro T et al (2014) Interventions for enhancing medication adherence. Cochrane Database Syst Ver 11:CD000011. \nhttps:\/\/doi.org\/10.1002\/14651858.cd000011.pub4","journal-title":"Cochrane Database Syst Ver"},{"issue":"9","key":"1209_CR21","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1345\/aph.1G094","volume":"39","author":"JL Praska","year":"2005","unstructured":"Praska JL, Kripalani S, Seright AL, Jacobson TA (2005) Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother 39(9):1441\u20131445. \nhttps:\/\/doi.org\/10.1345\/aph.1G094","journal-title":"Ann Pharmacother"},{"issue":"8","key":"1209_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120(8):713\u2013719. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2006.08.033","journal-title":"Am J Med"},{"issue":"8","key":"1209_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296\u20131310. \nhttps:\/\/doi.org\/10.1016\/S0149-2918(01)80109-0","journal-title":"Clin Ther"},{"issue":"11","key":"1209_CR24","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1185\/03007990903297741","volume":"25","author":"S Balu","year":"2009","unstructured":"Balu S, Simko RJ, Quimbo RM, Cziraky MJ (2009) Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 25(11):2765\u20132775. \nhttps:\/\/doi.org\/10.1185\/03007990903297741","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1209_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","volume":"165","author":"RH Chapman","year":"2005","unstructured":"Chapman RH, Benner JS, Petrilla AA et al (2005) Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165(10):1147\u20131152. \nhttps:\/\/doi.org\/10.1001\/archinte.165.10.1147","journal-title":"Arch Intern Med"},{"issue":"2","key":"1209_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s13760-019-01143-1","volume":"119","author":"A Varma","year":"2019","unstructured":"Varma A, Zis P (2019) Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials. Acta Neurol Belg 119(2):257\u2013264. \nhttps:\/\/doi.org\/10.1007\/s13760-019-01143-1","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"1209_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00023210-200721060-00004","volume":"21","author":"IB Kulaksizoglu","year":"2007","unstructured":"Kulaksizoglu IB (2007) Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 21(6):473\u2013481. \nhttps:\/\/doi.org\/10.2165\/00023210-200721060-00004","journal-title":"CNS Drugs"},{"issue":"2A","key":"1209_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1590\/s0004-282x2011000200006","volume":"69","author":"MI Ybarra","year":"2011","unstructured":"Ybarra MI, Kummer A, Frota ERC, de Oliveira JT, Gomez RS, Teixeira AL (2011) Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr 69(2A):176\u2013179. \nhttps:\/\/doi.org\/10.1590\/s0004-282x2011000200006","journal-title":"Arq Neuropsiquiatr"},{"issue":"11","key":"1209_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1525-1497.2006.00586.x","volume":"21","author":"IM Kronish","year":"2006","unstructured":"Kronish IM, Rieckmann N, Halm EA et al (2006) Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med 21(11):1178\u20131183. \nhttps:\/\/doi.org\/10.1111\/j.1525-1497.2006.00586.x","journal-title":"J Gen Intern Med"},{"issue":"2A","key":"1209_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1590\/s0004-282x2009000200006","volume":"67","author":"P Scalzo","year":"2009","unstructured":"Scalzo P, Kummer A, Cardoso F, Teixeira AL (2009) Depressive symptoms and perception of quality of life in Parkinson\u2019s disease. Arq Neuropsiquiatr 67(2A):203\u2013208. \nhttps:\/\/doi.org\/10.1590\/s0004-282x2009000200006","journal-title":"Arq Neuropsiquiatr"},{"key":"1209_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-019-01102-w","author":"UK Misra","year":"2019","unstructured":"Misra UK, Kalita J, Singh VK, Kumar S (2019) A study of comorbidities in myasthenia gravis. Acta Neurol Belg. \nhttps:\/\/doi.org\/10.1007\/s13760-019-01102-w","journal-title":"Acta Neurol Belg"},{"issue":"14","key":"1209_CR32","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","volume":"160","author":"MR DiMatteo","year":"2000","unstructured":"DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 160(14):2101\u20132107. \nhttps:\/\/doi.org\/10.1001\/archinte.160.14.2101","journal-title":"Arch Intern Med"},{"issue":"2","key":"1209_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/mus.23296","volume":"46","author":"EHM De Lapiscina","year":"2012","unstructured":"De Lapiscina EHM, Aguirre MEE, Blanco TA, Pascual IJ (2012) Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve 46(2):174\u2013180. \nhttps:\/\/doi.org\/10.1002\/mus.23296","journal-title":"Muscle Nerve"},{"issue":"1","key":"1209_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10072-009-0167-y","volume":"31","author":"A Raggi","year":"2010","unstructured":"Raggi A, Leonardi M, Antozzi C et al (2010) Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci 31(1):41\u201345. \nhttps:\/\/doi.org\/10.1007\/s10072-009-0167-y","journal-title":"Neurol Sci"},{"issue":"7","key":"1209_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6061\/clinics\/2016(07)03","volume":"71","author":"A Mour\u00e3o","year":"2016","unstructured":"Mour\u00e3o A, Gomez R, Barbosa L et al (2016) Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics 71(7):370\u2013374. \nhttps:\/\/doi.org\/10.6061\/clinics\/2016(07)03","journal-title":"Clinics"},{"issue":"23","key":"1209_CR36","doi-asserted-by":"publisher","first-page":"e10962","DOI":"10.1097\/MD.0000000000010962","volume":"97","author":"I Straka","year":"2018","unstructured":"Straka I, Min\u00e1r M, Ga\u017eov\u00e1 A, Valkovi\u010d P, Kyselovi\u010d J (2018) Clinical aspects of adherence to pharmacotherapy in Parkinson disease: a PRISMA-compliant systematic review. Medicine (United States). 97(23):e10962. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000010962","journal-title":"Medicine (United States)."}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01209-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T02:32:01Z","timestamp":1600914721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01209-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01209-0","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"22 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}